SPOTLIGHT: More data on Cell Genesys' GVAX


Shares of Cell Genesys jumped 21 percent this morning after the company announced that follow-up data from a mid-stage trial showed that prostate cancer patients taking its GVAX therapy survived longer than patients in a previous study. In the study, 22 patients survived an average of 35 months. Release